No Data
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $43
UBS analyst Trung Huynh maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and adjusts the target price from $52 to $43.According to TipRanks data, the analyst has a success rate of 75.5%
Express News | Bristol-Myers Squibb Co : UBS Cuts Target Price to $43 From $47
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $41
Barclays analyst Carter Gould maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 57.7%
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $37
Morgan Stanley analyst Terence Flynn maintains $Bristol-Myers Squibb(BMY.US)$ with a sell rating, and adjusts the target price from $40 to $37.According to TipRanks data, the analyst has a success
Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY)
102188459 : Tq
101884230 : Tq
Clement Lemons : OK
103677010 : noted
章允量 :
View more comments...